Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Helgebostad, Rasmus; Revheim, Mona-Elisabeth; Johnsrud, Kjersti; Amlie, Kristine; Alavi, Abass; Connelly, James Patrick

doi:10.3390/diagnostics12020528

Open AccessReview

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

by

Rasmus Helgebostad

¹,

Mona-Elisabeth Revheim

^1,2

,

Kjersti Johnsrud

¹,

Kristine Amlie

¹,

Abass Alavi

³ and

James Patrick Connelly

^1,*

¹

Division of Radiology and Nuclear Medicine, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424 Oslo, Norway

²

Institute of Clinical Medicine, University of Oslo, P.O. Box 1171 Blindern, 0318 Oslo, Norway

³

Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA

^*

Author to whom correspondence should be addressed.

Diagnostics 2022, 12(2), 528; https://doi.org/10.3390/diagnostics12020528

Submission received: 19 December 2021 / Revised: 14 February 2022 / Accepted: 16 February 2022 / Published: 18 February 2022

(This article belongs to the Section Medical Imaging and Theranostics)

Download

Browse Figures

Versions Notes

Abstract

Somatostatin receptor (SSTR) agonist tracers used in nuclear medicine scans are classically used for neuroendocrine tumor diagnosis and staging. SSTR are however, expressed more widely in a variety of cells as seen in the distribution of physiological tracer uptake during whole body scans. This provides opportunities for using these tracers for applications other than NETs and meningiomas. In this qualitative systematic review, novel diagnostics in SSTR-PET imaging are reviewed. A total of 70 studies comprised of 543 patients were qualitatively reviewed. Sarcoidosis, atherosclerosis and phosphaturic mesenchymal tumors represent the most studied applications currently with promising results. Other applications remain in progress where there are many case reports but a relative dearth of cohort studies. [¹⁸F]FDG PET provides the main comparative method in many cases but represents a well-established general PET technique that may be difficult to replace, without prospective clinical studies.

Keywords: somatostatin; PET; imaging; review; inflammation; benign; malignant; sarcoidosis; atherosclerosis; osteomalacia

Share and Cite

MDPI and ACS Style

Helgebostad, R.; Revheim, M.-E.; Johnsrud, K.; Amlie, K.; Alavi, A.; Connelly, J.P. Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors. Diagnostics 2022, 12, 528. https://doi.org/10.3390/diagnostics12020528

AMA Style

Helgebostad R, Revheim M-E, Johnsrud K, Amlie K, Alavi A, Connelly JP. Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors. Diagnostics. 2022; 12(2):528. https://doi.org/10.3390/diagnostics12020528

Chicago/Turabian Style

Helgebostad, Rasmus, Mona-Elisabeth Revheim, Kjersti Johnsrud, Kristine Amlie, Abass Alavi, and James Patrick Connelly. 2022. "Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors" Diagnostics 12, no. 2: 528. https://doi.org/10.3390/diagnostics12020528

APA Style

Helgebostad, R., Revheim, M.-E., Johnsrud, K., Amlie, K., Alavi, A., & Connelly, J. P. (2022). Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors. Diagnostics, 12(2), 528. https://doi.org/10.3390/diagnostics12020528

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI